SG11201407595UA - Generation of human ips cells by a synthetic self- replicative rna - Google Patents

Generation of human ips cells by a synthetic self- replicative rna

Info

Publication number
SG11201407595UA
SG11201407595UA SG11201407595UA SG11201407595UA SG11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA SG 11201407595U A SG11201407595U A SG 11201407595UA
Authority
SG
Singapore
Prior art keywords
nsp1
nsp4
nsp2
vee
international
Prior art date
Application number
SG11201407595UA
Inventor
Steven F Dowdy
Naohisa Yoshioka
Original Assignee
Univerisity Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univerisity Of California filed Critical Univerisity Of California
Publication of SG11201407595UA publication Critical patent/SG11201407595UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/177133 A2 (51) International Patent Classification: Not classified (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/041980 21 May 2013 (21.05.2013) English (30) Priority Data: 61/649,876 61/798,229 21 May 2012 (21.05.2012) 15 March 2013 (15.03.2013) English US US (84) (71) Applicant: THE REGENTS OF THE UNIVERISITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 5th Floor, Oakland, California 94607-5200 (US). (72) Inventors: DOWDY, Steven, F.; 5761 Waverly Avenue, La Jolla, CA 92037 (US). YOSHIOKA, Naohisa; 7665 Palmilla Drive, #5420, San Diego, CA 92122 (US). (74) Agent: BAKER, JR., Joseph, R.; Gavrilovich, Dodd & Lindsey LLP, 4660 La Jolla Village Drive, Suite 750, San Diego, CA 92122 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: GENERATION OF HUMAN IPS CELLS BY A SYNTHETIC SELF- REPLICATIVE RNA A) CJ m m i-H l> l> Non-Structural Proteins Structural Proteins orTransgenes VEE -| nsP1 | nsP2 | nsP3 | nsP4 Ml C I E2 E1 | H (-11,700 nt) VEE-GFP -| nsP1 I nsP2 | nsP3 | nsP4~HHPIilll' sl (-9,650 nt) VEE-OS H nsP1 I nsP2 I nsP3 nsP4 I MlQct4 jSoxZflillN' (~11,000nt) VEE-OMKS ^ nsP1 | nsP2 I risP3 | nsP4 Hi|Oct4 § cMyc | Klf4 jSox2| VEE-OKS-iM H nsP1 I nsP2 I nsP3 nsP4 I Mioct4lKlf4 i I cMyc VEE-OKS-iG -I nsP1 I nsP2 I nsP3 nsP4 I H;lOct4 i Klf4 §Sox2§ Ollstt |26S Pr 12A-peptide glRES Puro r EB 3'UTR & PolyA =PCR (-13,900 nt) (-14,500 nl) (-15,000 nt) i-H (57) Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and ® use thereof. CJ o &
SG11201407595UA 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna SG11201407595UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649876P 2012-05-21 2012-05-21
US201361798229P 2013-03-15 2013-03-15
PCT/US2013/041980 WO2013177133A2 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna

Publications (1)

Publication Number Publication Date
SG11201407595UA true SG11201407595UA (en) 2014-12-30

Family

ID=49624495

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407595UA SG11201407595UA (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna

Country Status (14)

Country Link
US (4) US9862930B2 (en)
EP (1) EP2852671B1 (en)
JP (1) JP6396893B2 (en)
CN (1) CN104508131B (en)
AU (1) AU2013266496B2 (en)
CA (1) CA2873964A1 (en)
DK (1) DK2852671T3 (en)
ES (1) ES2698527T3 (en)
HU (1) HUE041853T2 (en)
IL (2) IL235628B (en)
PL (1) PL2852671T3 (en)
PT (1) PT2852671T (en)
SG (1) SG11201407595UA (en)
WO (1) WO2013177133A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106572974B (en) 2014-07-15 2021-04-23 生命技术公司 Compositions and methods having lipid aggregates for efficient delivery of molecules to cells
CA3005739A1 (en) * 2015-11-18 2017-05-26 Orbis Health Solutions Llc T7 alpha viral vector system
US20190352604A1 (en) * 2017-02-24 2019-11-21 Koji Tanabe Nerve cell production method
WO2018155595A1 (en) * 2017-02-24 2018-08-30 剛士 田邊 Production method for artificial pluripotent stem cells
EP3648750A4 (en) * 2017-07-05 2021-05-26 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
CA3075549A1 (en) * 2017-09-13 2019-03-21 Biontech Rna Pharmaceuticals Gmbh Rna replicon for reprogramming somatic cells
US11229699B2 (en) * 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
EP3719133A4 (en) * 2017-11-30 2021-08-11 I Peace, Inc. Method for producing neural cells
KR102143320B1 (en) 2018-08-28 2020-08-12 주식회사 스템랩 METHODS FOR DIRECT CONVERTION OF HUMAN URINE CELLS INTO NEURAL STEM CELLS USING A SYNTHETIC mRNA
BR112021006614A2 (en) * 2018-10-08 2021-07-20 Janssen Pharmaceuticals, Inc. alphavirus-based replicons for biotherapeutic administration
WO2020146690A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
JP2022538847A (en) * 2019-06-27 2022-09-06 イーエムディ・ミリポア・コーポレイション Cell proliferation with self-replicating RNA vectors expressing immortalizing proteins
EP4085130A4 (en) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
CN115484990A (en) 2020-03-12 2022-12-16 基础科学研究院 Composition for inducing apoptosis having genomic sequence variation and method for inducing apoptosis using the same
US20230220025A1 (en) * 2020-09-04 2023-07-13 Heartseed Inc. Quality Improving Agent for IPS Cells, Method of Producing IPS Cells, IPS Cells, and Composition for Producing IPS Cells
CN112458064A (en) * 2020-11-20 2021-03-09 广西大学 Gatasavir full-length infectious clone, replicon system, preparation and application thereof
CN112852841A (en) * 2021-02-03 2021-05-28 郑州大学 Cis replicon RNA construct for efficiently expressing target protein
EP4314249A1 (en) 2021-03-25 2024-02-07 Bluerock Therapeutics LP Methods for obtaining induced pluripotent stem cells
WO2022234268A1 (en) * 2021-05-04 2022-11-10 Mogrify Limited Cell conversion
WO2023288285A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Polycistronic expression vectors
WO2023288288A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
WO2023288287A2 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
WO2023122517A2 (en) * 2021-12-20 2023-06-29 Elevatebio Technologies, Inc. Compositions and methods for cellular reprogramming using circular rna
WO2023212722A1 (en) 2022-04-28 2023-11-02 Bluerock Therapeutics Lp Novel sites for safe genomic integration and methods of use thereof
WO2023250197A2 (en) 2022-06-23 2023-12-28 Turn Biotechnologies, Inc. Lipid structures and compositions comprising same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ATE244065T1 (en) 1990-12-06 2003-07-15 Affymetrix Inc METHODS AND REAGENTS FOR VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS
JP4383530B2 (en) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド Alphavirus vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
ATE437222T1 (en) 2001-09-06 2009-08-15 Alphavax Inc ALPHAVIRUS REPLICON VECTOR SYSTEMS
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
DK2290054T3 (en) 2002-12-13 2017-07-03 Alphavax Inc Alpha virus particles and processes for their preparation
CA2518546C (en) 2003-03-20 2012-11-13 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US9005966B2 (en) 2007-11-19 2015-04-14 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
WO2009152529A2 (en) * 2008-06-13 2009-12-17 Whitehead Institute For Biomedical Research Nine Cambridge Center Programming and reprogramming of cells
WO2010028019A2 (en) 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
CN102388136B (en) 2009-02-27 2014-10-01 国立大学法人京都大学 Novel nuclear reprogramming substance
ES2540958T3 (en) 2009-04-08 2015-07-15 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
EP2401361A4 (en) 2009-04-13 2013-09-04 Univ California Methods and compositions for stem cell cultures
US20130196865A1 (en) * 2010-03-03 2013-08-01 The General Hospital Corporation Method for selecting an ips cell
US8802438B2 (en) * 2010-04-16 2014-08-12 Children's Medical Center Corporation Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
TR201809547T4 (en) * 2012-11-09 2018-07-23 Biontech Rna Pharmaceuticals Gmbh Method for cellular RNA expression.

Also Published As

Publication number Publication date
HUE041853T2 (en) 2019-05-28
EP2852671A4 (en) 2015-12-23
DK2852671T3 (en) 2018-12-10
ES2698527T3 (en) 2019-02-05
CN104508131B (en) 2018-11-23
JP6396893B2 (en) 2018-09-26
US20150159143A1 (en) 2015-06-11
IL235628A0 (en) 2015-01-29
WO2013177133A3 (en) 2014-03-20
US20190338252A1 (en) 2019-11-07
WO2013177133A2 (en) 2013-11-28
CA2873964A1 (en) 2013-11-28
IL272917A (en) 2020-04-30
PL2852671T3 (en) 2019-06-28
EP2852671B1 (en) 2018-08-22
AU2013266496B2 (en) 2018-08-09
IL235628B (en) 2020-03-31
US9862930B2 (en) 2018-01-09
US20210108179A1 (en) 2021-04-15
AU2013266496A1 (en) 2014-11-27
JP2015519898A (en) 2015-07-16
US20180216079A1 (en) 2018-08-02
US10793833B2 (en) 2020-10-06
EP2852671A2 (en) 2015-04-01
CN104508131A (en) 2015-04-08
PT2852671T (en) 2018-11-29
US10370646B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
SG11201407595UA (en) Generation of human ips cells by a synthetic self- replicative rna
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201407427WA (en) Extreme pcr
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201407561UA (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407702XA (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
SG11201810782TA (en) Elastomeric copolymers based on [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and their use in the preparation of rubbers
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201903450YA (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
SG11201407867VA (en) Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
SG11201408561YA (en) Tunable materials
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201407635XA (en) Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201809594WA (en) Nicotine particles and compositions